Metastasis is the main cause of tumour mortality. It is a multi-step process that relies on the ability of cancer cells to dissociate from primary sites, survive in the vascular and lymphatic systems, and colonise and proliferate in distant target organs ([@bib20]). Most normal epithelial and endothelial cells adhere to their appropriate extracellular matrix (ECM) through specific integrins, which leads to the activation of cell survival signals. If these cells detach from the ECM or engage with an inappropriate ECM, they undergo anoikis, also known as cell detachment-induced apoptosis ([@bib31]; [@bib11]). Anoikis is important for maintaining tissue homeostasis and is essential for preventing the dissemination of cells to inappropriate sites. Normal cells are highly sensitive to anoikis, but some cancer cells acquire anoikis resistance and are able to survive without ECM adhesion in the circulation. Because anoikis provides a critical barrier to the survival of invading cancer cells in the circulatory system, anoikis resistance is an essential prerequisite for tumour metastasis ([@bib20]). Therefore, understanding the cellular and molecular mechanisms that confer anoikis resistance may lead to the identification of novel therapeutic targets to treat and prevent tumour metastasis.

Although the mechanisms of anoikis resistance are not fully understood, studies have demonstrated that reactive oxygen species (ROS) regulate anoikis resistance either positively or negatively, indicating dual effects of ROS depending on cell context ([@bib6]; [@bib13]). It has been reported that growth factor receptors and ROS can mediate the activation of survival signalling pathways, leading to the anoikis resistance of cancer cells ([@bib13]). Activation of growth factor receptors increases ROS production by activating ROS-generating enzymes such as NADPH oxidase (NOX) and lipoxygenase ([@bib12]; [@bib4]; [@bib13]). The NOX family member NADPH oxidase 4 (NOX4) is highly expressed in the kidney and blood vessels, and its physiological and pathological roles have been widely studied in hypertension, atherosclerosis, diabetes, and fibrosis ([@bib2]; [@bib21]). Recently, NOX4 has been shown to be associated with several cancers such as glioblastoma, melanoma, and thyroid carcinoma ([@bib35]; [@bib34]; [@bib19]; [@bib28]; [@bib3]; [@bib5]; [@bib23]). In melanoma cells, NOX4 contributes to the transformation phenotype by regulating G2-M cell cycle progression and enhancing cell survival via activation of Akt ([@bib35]). Furthermore, in urinary bladder cancer cells, NOX4 inhibition induces cell cycle arrest via p16 induction ([@bib28]). NOX4 has also been shown to be critical for renal tumourigenesis by promoting the nuclear accumulation of hypoxia-inducible factor 2α (HIF2α ([@bib16]).

Elevated ROS levels are frequently observed in tumours where they induce prosurvival signals through the activation of Src and EGFR ([@bib13]). Activation of the EGFR initiates signalling pathways that promote cell proliferation, migration, and survival, thereby contributing to tumour progression ([@bib32]). Moreover, enhanced activity of EGFR, via overexpression and mutation, is highly associated with several solid tumour malignancies ([@bib32]). Interestingly, EGFR downregulation is associated with anoikis. Upon detachment of a cell from ECM, CCN family protein 2 (CCN2) binds and triggers EGFR degradation, which increases death-associated protein kinase and promotes anoikis ([@bib7]). In addition, ECM detachment upregulates the proapoptotic protein, Bim, which lead to anoikis. However, overexpression of EGFR blocks anoikis by inhibiting Bim expression ([@bib27]). Furthermore, in breast epithelial cells, the oncogene HER2 stabilises EGFR in ECM-detached cells via activation of the ERK/Sprouty2 pathway ([@bib15]). These studies indicate that maintenance of EGFR levels/activity is important for anoikis resistance.

In this study, we demonstrate that detachment of lung cancer cells induces *NOX4* expression and increases ROS production, which is critical for the downstream activation of Src and EGFR. We also demonstrate that NOX4 upregulation attenuates EGFR downregulation and maintains EGFR levels and activity during cell detachment, which confers anoikis resistance of lung cancer cells. We further showed that NOX4 expression is upregulated and is positively correlated with EGFR expression in the lung cancer patients.

Materials and methods
=====================

Cell culture
------------

The human lung adenocarcinoma cell line, A549 was purchased from ATCC (American Type Culture Collection). The human bronchial epithelial cell line, BEAS-2B was a kind gift from Yeul Hong Kim (Korea University, Korea). The human lung cancer cell lines, NCI H1703, Calu-6, NCI H460, NCI H358, HCC2279 were from Dr Kyungsil Yoon (National Cancer Center, Korea). BEAS-2B cells were maintained in Keratinocyte-SFM (Invitrogen, Carlsbad, CA, USA) with supplements (30 *μ*g/ml Bovine Pituitary Extract and 0.2 ng ml^−1^ rEGF; Invitrogen). A549, NCI H1703, Calu-6, NCI H460, NCI H358, HCC 2279 cells were maintained in RPMI 1640 (Hyclone, Rockford, IL, UAS) supplemented with 10% fetal bovine serum (Hyclone) and 1% penicillin and streptomycin (Invitrogen, San Diego, CA, USA) in a 5% CO~2~ atmosphere at 37 °C.

Antibodies and reagents
-----------------------

NOX4 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), Novus Biologicals (Littleton, CO, USA) and Abcam (Cambridge, UK). NOX2 antibody was purchased from Abcam. Phosphorylated EGFR antibodies (Y845, Y1068, and Y992), Hoechest 33342 and Alexa Fluor 488 goat anti-mouse IgG were purchased from Invitrogen. Anti-EGFR, anti-c-Src, anti-p22^phox^, horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG, HRP-conjugated goat anti-rabbit IgG antibodies were obtained from Santa Cruz Biotechnology. Anti-Bim antibody was purchased from Enzo Life Sciences (Farmingdale, NY). anti-Akt, Anti-phospho Akt (S473), anti- ERK1&2, anti-phospho ERK1&2 (T202/Y204), anti-phospho Src (Y416), anti-phospho EGFR (Y1068), anti-phospho GSK3*β* (S9), anti-STAT3, and anti-cleaved caspase-3 were obtained from Cell Signaling Technology (Beverly, MA). Anti-EGFR (528) antibody was purchased from Abcam. Anti-β-actin antibody, Dimethyl sulfoxide (DMSO), N-acetylcysteine (NAC), Diphenyleneiodonium (DPI), apocynin, plumbagin and Poly (2-hydroxyethyl methacrylate) (Poly-HEMA) were purchased from Sigma (St. Louis, Missouri).

Small interfering RNA preparation and transfection
--------------------------------------------------

Validated small interfering RNA (siRNA) duplexes for human *NOX4* (SC-41586) and human *EGFR* (SC-29301) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and a negative control with a scrambled sequence (SN-1003) was purchased from Bioneer (Daejeon, Korea). A549 cells were reverse transfected with 60 pmol siRNA using Lipofectamine RNAiMAX reagent (Invitrogen) according to the manufacturer\'s protocol. The A549 cells were trypsinised 24 h post-transfection and cultured in attached or suspended conditions. The siRNA sequences used to target *NOX4* is 5′-AACGAAGGGGUUAAACACCUC-3′ and *EGFR* is 5′-CUCUGGAGGAAAAGAAAGU-3′.

Immunoblotting
--------------

After washing with ice-cold PBS, cells were lysed with 2X SDS sample buffer (20 m[M]{.smallcaps} Tris (pH 8.0), 2% SDS, 2 m[M]{.smallcaps} DTT, 1 m[M]{.smallcaps} Na~3~VO~4~, 2 m[M]{.smallcaps} EDTA, 20% glycerol) and boiled for 5 min. The protein concentration of each sample was determined using a BCA protein assay reagent (Pierce, Rockford, IL) as described by the manufacturer. In all, 20--50 *μ*g of total cellular protein were separated by 8--12% SDS-PAGE and transferred to PVDF membranes. The membranes were blocked for 1 h at room temperature in Tris-buffered saline and Tween-20 \[TBS-T, 20 m[M]{.smallcaps} Tris (pH 8.0), 150 m[M]{.smallcaps} NaCl and 0.1% Tween-20) containing 5% non-fat dried milk. The membranes were incubated with primary antibody overnight at 4 °C, washed three times with TBS-T, incubated with horseradish peroxidase-conjugated goat anti-mouse IgG or goat anti-rabbit IgG secondary antibodies for 1 h at room temperature, and then washed three times with TBS-T. The labelled proteins were visualised using the chemiluminescence method. The film was scanned, and the protein bands were quantified by densitometric analysis using ImageJ software (<http://rsb.info.nih.gov/ij/>).

Suspension culture and anoikis assay
------------------------------------

Tissue culture plates (60 mm) were coated with 250 μl of poly-HEMA (50 mg ml^−1^ in 95% ethanol) and dried overnight in a laminar flow hood at room temperature. Cells were trypsinised into a single cell suspension, and 8 × 10^5^ cells were plated on poly-HEMA-coated dishes. After 24 h, the cells were collected by centrifugation and processed for cell viability, flow cytometric analysis, and protein analysis. For the anoikis assay, collected cells were washed with PBS, cell aggregates were removed with AccuMax (Innovative Cell Technologies, San Diego, CA, USA), and cell survival was determined using trypan blue exclusion. Alternatively, cell viability was analysed using the Live/Dead Viability/Cytotoxicity Kit (Invitrogen) as described in the manufacturer\'s instructions. Briefly, cells were stained with 0.8 *μ*[M]{.smallcaps} green-fluorescent Calcein AM and 4 *μ*[M]{.smallcaps} red-fluorescent ethidium homodimer-1 for 30 min at room temperature. The labelled cells (green=live cells, red=dead cells) were analysed using an Axio Observer Z1 fluorescence microscope (Carl Zeiss Microimaging, Thornwood, NY, USA) and an Axion Vision camera (Axion Technologies, Houston, TX, USA).

Production of NOX4-expressing lentivirus
----------------------------------------

The NOX4/pCMV-SPORT6 vector was obtained from 21C Frontier Human Gene Bank (KRIBB, Daejeon, Korea). Lentivirus was produced using the Viralpower Lentiviral Expression System (Invitrogen). Briefly, the NOX4 open reading frame (ORF) was amplified from the NOX4/pCMV-SPORT6 vector using the following primers: forward (5′-CCCGGGACCATGGCTGTGTCC-3′) and reverse (5′-GCGGCCGCTCAGCTGAAAGACTC-3′). The NOX4 cDNA was subcloned into the pLenti6/V5-D-TOPO vector according to the manufacturer\'s protocol. The resultant NOX4/pLenti6-D-TOPO vector was verified using PCR, restriction digestion, and sequence analysis (Macrogen, Seoul, Korea). The pLenti6/V5-GW/lacZ (Invitrogen) vector was used as a positive control. Recombinant lentiviruses were produced according to the manufacturer\'s protocol (Invitrogen). Briefly, we co-transfected the pLenti6/V5-D-TOPO (NOX4 or LacZ) vector and the Lentiviral Packaging Mix (Invitrogen) into 293 FT cells. After 48 h, the viral supernatant was collected, spun to remove cell debris, filtered through a Millex-HV syringe filter (0.45 μm, Millipore, Bedford, MA, USA), and stored at −80 °C.

NOX4 overexpression in A549 cells
---------------------------------

A549 cells were infected with the lentiviral supernatants and 2 *μ*g ml^−1^ polybrene (hexadimethrine bromide). After 24 h, the medium was changed, and then the cells were incubated for 48 h prior to selection in 10 *μ*g ml^−1^ blasticidin-containing media for 14 days to generate stable cell lines. The expression of respective proteins was verified via immunoblot analysis.

Microarray analysis
-------------------

Microarray experiments were performed using tools from the commercial microarray service Ebiogen, Inc. (Seoul, Korea). Total RNA was isolated from A549 cells grown in attachment or suspension conditions using Trizol reagent (Invitrogen) according to the manufacturer\'s instructions. The isolated RNA was amplified and subjected to cDNA microarray (Ebiogen). Briefly, amplified cRNA was hybridised to Agilent\'s Human Oligo Microarray (44 K) (Agilent Technology, Palo Alto, CA, USA). The hybridised images were scanned using Agilent\'s DNA microarray scanner and quantified with Feature Extraction Software (Agilent Technology). The data normalisation and selection of fold-changed genes were performed using GeneSpring GX 7.3 (Agilent Technology). The averages of normalised ratios were calculated by dividing the average of normalised signal channel intensity by the average of normalised control channel intensity. The functional annotation of genes was performed according to Gene Ontology Consortium (<http://www.geneontology.org/index.shtml>) by GeneSpringGX 7.3. The gene classification was based on searches done by BioCarta (<http://www.biocarta.com>), GenMAPP (<http://www.genmapp.org>), DAVID (<http://david.abcc.ncifcrf.gov>) and Medline databases (<http://www.ncbi.nlm.nih.gov>).

Reverse transcription-polymerase chain reaction (RT-PCR)
--------------------------------------------------------

After total RNA extraction, single-stranded cDNA was generated using Maxime RT PreMix (Oligo dT~15~ Primer; iNtRON Biotechnology, Kyungki-Do, Korea) following the manufacturer\'s directions. Synthesised cDNA fragments were amplified with the following primer pairs: *ACTB*, 5′-ACAACGGCTCCGGCATGTGCAA-3′ (sense) and 5′-CGGTTGGCCTTGGGGTTCAG-3′ (anti-sense); *GAPDH*, 5′-CTTTGGTATCGTGGAAGGA-3′ (sense) and 5′-CACCCTGTTGCTGTAGCC-3′ (anti-sense); *NOX4*, 5′-AGGAGAACCAGGAGATTGTTG-3′ (sense) and 5′-GGGATGACTTATGACCGAAAT-3′ (anti-sense); *p22*^*phox*^, 5′-GTGTTTGTGTGCCTGCTGGAGT-3′ (sense) and 5′-CTGGGCGGCTGCTTGATGGT-3′ (anti-sense); *EGFR*, 5′-GCAAATAAACCGGACTGAAG-3′ (sense) and 5′-GTGGCACCAAAGCTGTATTTG-3′ (anti-sense); *NOX2*, 5′-GGGCTGTTCAATGCTTGTGGCT-3′ (sense) and 5′-ACATCTTTCTCCTCATCATGGTGC-3′ (anti-sense); *NOX5*, 5′-ATCAAGCGGCCCCCTTTTTTTCAC-3′ (sense) and 5′-CTCATTGTCACACTCCTCGACAGC-3′ (anti-sense). PCR was performed using a T-Gradient Thermal Cycler (Biometra, Goettingen, Germany) and AccuPower PCR Premix (Bioneer) according to the manufacturer\'s protocol. *ACTB* and *GAPDH* were used as the housekeeping genes. The PCR products were resolved on 1.5% agarose gels and visualised using a BioDoc-it Imaging System (UVP, Upland, CA, USA).

Flow cytometry analysis
-----------------------

For ROS measurements, A549 cells grown in attachment or suspension conditions were incubated with 20 *μ*[M]{.smallcaps} of CM-H~2~DCFDA for 40 min at 37 °C, collected, and analysed by flow cytometry using a FACSCalibur (Becton Dickinson Bioscience, San Jose, CA, USA). To quantify EGFR surface expression levels, cells were trypsinised and suspended in PBS containing 1% FBS. Approximately 5 × 10^5^ cells were stained for 30 min with either monoclonal anti-EGF receptor antibody (mAb 528) or IgG isotype control. The cells were then washed with ice-cold PBS and incubated for 30 min with Alexa 488-conjugated secondary IgG anti-mouse (1 μg of antibody/2 × 10^5^ cells in 100 *μ*l) for 30 min. The cells were subsequently washed with ice-cold PBS and analysed using FACSCalibur. All antibody incubations and washing steps were carried out at 4 °C. The raw data were analysed by Cell Quest Software (BD Bioscience) at the flow cytometry core facility of the National Cancer Center (Gyeonggi-do, Korea).

Immunofluorescence and confocal microscopy imaging
--------------------------------------------------

Cells grown on cover slips were fixed with 3.7% paraformaldehyde in PBS on ice for 20 min, and then rinsed with PBS. The fixed cells were treated with 1.5 mg ml^−1^ glycine in PBS to quench the free aldehyde groups, blocked with 3% BSA in PBS for 1 h at room temperature, and rinsed with PBS. The cells were stained with anti-EGFR antibodies (mAb 528) or non-specific IgG overnight at 4 °C, washed with PBS, and then exposed to Alexa 488-conjugated secondary IgG for 1 h at room temperature. For nuclear staining, the cells were incubated with Hoechst 33342 in PBS for 5 min at room temperature. The cover slips were washed in PBS and mounted on glass slides. Immunofluorescence was measured on a Zeiss LSM 510 laser scanning microscope (Carl Zeiss, Jena, Germany).

Soft agar assay
---------------

A549 cells were transfected with si-control, si-*NOX4*, or si-*EGFR* for 24 h and soft agar assays were performed in 35 mm plates by placing 1 × 10^3^ cells in 1 ml of 0.3% agar onto a base layer 1 ml of 0.8% agar. The plates were then covered with 1 ml of fresh RPMI medium containing 10% FBS and incubated in a 5% CO~2~ atmosphere at 37 °C for 2 weeks. Cell growth medium was changed every third day. Colonies were stained with iodonitro tetrazolium violet (INT) solution (Sigma, 0.5 mg ml^−1^) and images were taken by Kodak Image Station 2000R (Eastman Kodak Company, New Haven, CT, USA).

Immunohistochemical staining for lung cancer tissue microarray
--------------------------------------------------------------

Tissue arrays were obtained from Superbiochips Laboratories (Seoul, Korea) that has been described previously ([@bib30]). Each array contained 60 sections of 4 *μ*m thickness obtained from 60 patients by biopsy or surgical resection. The primary antibodies used were polyclonal rabbit anti-NOX4 (1 : 100 dilutions; Novus Biologicals) and polyclonal rabbit anti-EGFR antibody (1 : 100 dilutions; Santa Cruz Biotechnology). The tumour tissues incubated with primary antibodies for 1 h were then treated with anti-rabbit biotinylated antibody (1 : 1000 dilutions; Vector Laboratories) for 1 h. Colour reaction was developed by incubation with diaminobenzidine solution (Sigma) followed by counter staining with hematoxylin. Parallel sections incubated with normal IgG instead of primary antibodies were used as negative controls. The overall staining results were scored from 0 to 3 based on the intensity and positive rate of staining. Intensity of staining was categorised as 0, negative (−); 1, weak (+); 2, intermediate (++); 3, strong (+++). Stained tissue arrays were reviewed by two experienced pathologists.

Statistical analysis
--------------------

All data points represent average values and s.d. (error bars) obtained from three independent experiments performed in triplicate. Comparison between two groups was performed using Student\'s *t*-test. Statistical significance was defined as a *P*-value\<0.05. The relationship between NOX4 expression and clinocopathologic characteristics were analysed by Pearson\'s *χ*^2^ method.

Results
=======

Anoikis resistance in A549 human lung epithelial adenocarcinoma cells
---------------------------------------------------------------------

Normal epithelial cells are known to be sensitive to anoikis, whereas cancer cells often acquire anoikis resistance ([@bib20]). To compare anoikis sensitivity, we employed immortalised normal bronchial epithelial cells (BEAS-2B) and lung carcinoma cells (A549). When cultured in suspension, A549 cells formed larger cell aggregates at a more rapid rate than BEAS-2B cells and overall aggregate sise for the A549 cells was larger than that of BEAS-2B cells ([Figure 1A](#fig1){ref-type="fig"}). Cells in suspension that form mutlicellular aggregates are known to be more anoikis-resistant than single cells ([@bib38]). During suspension culture, A549 cell number increased, although the growth rate was very slow, whereas BEAS-2B cell number decreased ([Figure 1B](#fig1){ref-type="fig"}). In addition, caspase 3 activation determined by caspase 3 cleavage was enhanced in suspended BEAS-2B cells when compared with A549, suggesting that BEAS-2B cells are more sensitive to anoikis, than A549 cells ([Figure 1C](#fig1){ref-type="fig"}). Next, we examined changes in several signalling molecules that are important for cell survival. Although total levels of EGFR decreased in A549 cells grown in suspension, the level of phosphorylation of EGFR at multiple tyrosine residues including Y845 and Y1068 increased ([Figure 1D](#fig1){ref-type="fig"} and [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). In addition, A549 cells grown in suspension showed increased levels of activated Src and ERK1&2, as determined by their phosphorylation ([Figure 1D](#fig1){ref-type="fig"}), whereas Akt phosphorylation remained unchanged. However, we did not detect activation of these molecules in the normal BEAS-2B cells ([Figure 1D](#fig1){ref-type="fig"}), indicating that they are selectively activated in cancer cells to mediate anoikis resistance.

NOX4 upregulation and ROS generation in anoikis resistant A549 cells
--------------------------------------------------------------------

To examine differential gene expression that is dependent on cell adhesion, we performed mRNA expression arrays using RNA from A549 cells grown in suspension and adherent culture conditions. NADPH oxidase 4 (*NOX4*) showed a threefold increase in suspended cells compared with attached cells ([Figure 2A](#fig2){ref-type="fig"}). We validated *NOX4* upregulation at the mRNA and protein levels in suspended cells by RT-PCR and immunoblotting, respectively ([Figure 2B](#fig2){ref-type="fig"}). Interestingly, p22^phox^, a functional partner of NOX4 ([@bib2]; [@bib21]), was also increased from 4 h and remained increased at the mRNA and protein levels upon cell detachment ([Figure 2C](#fig2){ref-type="fig"}). However, *NOX2* and *NOX5*, other members of the NOX family, showed little change in their expression levels ([Figure 2D](#fig2){ref-type="fig"}).

Because we observed NOX4 and p22^phox^ upregulation in cells grown in suspension, we investigated differences between ROS generated from cells that were grown in suspended and attached conditions. Flow cytometry analysis of CM-H~2~DCFDA, a ROS-sensitive dye, revealed an increase in ROS levels in the suspended cells that was decreased by treatment with the ROS scavenger NAC and the NOX inhibitor diphenyleneiodonium (DPI) ([Figure 3A](#fig3){ref-type="fig"}). Cell viability was also decreased by treatment with the NOX inhibitors DPI and apocynin ([Figure 3B](#fig3){ref-type="fig"}). In addition, NOX inhibition in the suspension culture resulted in decreased activation of EGFR and Src ([Figure 3C](#fig3){ref-type="fig"}). However, NOX inhibitor, DPI did not affect EGFR phosphorylation in the attached A549 cells ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). More specifically, administration of plumbagin, which has been shown to inhibit NOX4 ([@bib9]), to cells grown in suspension, decreased cell aggregation and reduced ROS generation ([Figure 3D and E](#fig3){ref-type="fig"}). Consistent with the results using NOX inhibitors ([Figure 3B](#fig3){ref-type="fig"}), plumbagin treatment induced the death of suspended cells ([Figure 3F](#fig3){ref-type="fig"}), indicating that plumbagin sensitises cells to anoikis. Plumbagin treatment also decreased EGFR activation and this inhibition appeared to be selective because plumbagin had little effect on other pathways, including Akt activation ([Figure 3G](#fig3){ref-type="fig"}). These data indicate that cell detachment increases ROS production, probably through induction of NOX4 expression, and that increased ROS levels are critical for anoikis resistance.

To further investigate NOX4 involvement in anoikis resistance, we overexpressed NOX4 ([Figure 4A](#fig4){ref-type="fig"}) or depleted *NOX4* using siRNA ([Figure 4B](#fig4){ref-type="fig"}). NOX4 overexpression did not affect the growth of attached cells. However, knockdown of *NOX4* attenuated the growth of attached cells regardless of NOX4 overexpression ([Figure 4C](#fig4){ref-type="fig"}). In suspension culture, NOX4 overexpression caused a slight increase in cell aggregation, whereas *NOX4* depletion caused a notable inhibition in cell aggregation that was attenuated in the NOX4-overexpressing cells ([Figure 4C](#fig4){ref-type="fig"}). *NOX4* knockdown also induced cell death ([Figure 4D](#fig4){ref-type="fig"}) and increased caspase-3 activation ([Figure 4E](#fig4){ref-type="fig"}) in suspension culture condition. Accordingly, cell growth also decreased in *NOX4*-depleted cells compared with control cells ([Figure 4F](#fig4){ref-type="fig"}). These data indicate that increased NOX4 expression is essential for the anoikis resistance of suspended A549 cells.

NOX4 expression increases EGF receptor levels
---------------------------------------------

Because *NOX4* knockdown sensitised suspended cells to anoikis, and because EGFR is a well-known regulator of cell survival and anoikis resistance ([@bib27]), we tested whether NOX4 affects EGFR levels or activation. Interestingly, knockdown of NOX4 downregulated EGFR levels in both attached and detached cells ([Figure 5A](#fig5){ref-type="fig"}). In addition, the majority of EGFR was localised to the plasma membrane in the control cells, but its localisation shifted from the plasma membrane to the cytoplasm in the *NOX4*-knockdown cells ([Figure 5B](#fig5){ref-type="fig"}). Consistent with this observation, flow cytometry analysis demonstrated that cell surface levels of EGFR decreased in the *NOX4*-knockdown cells compared with control cells ([Figure 5C](#fig5){ref-type="fig"}). To further investigate the association of NOX4 with EGFR levels, we examined EGFR levels in the NOX4 overexpressing. EGFR levels were upregulated in the NOX4-overexpressing cells compared with mock cells in both attached and detached cells ([Figure 5D](#fig5){ref-type="fig"}). In addition, although EGFR levels decreased upon *NOX4* knockdown in NOX4-overexpressing and control cells, this decrease was attenuated in NOX4-overexpressing cells. However, *NOX4* knockdown did not reduce STAT3 total levels, suggesting that *NOX4* knockdown downregulates EGFR selectively ([Figure 5E](#fig5){ref-type="fig"}). EGFR overexpression is known to inhibit anoikis by downregulation of a pro-apoptotic protein, Bim ([@bib27]). Because NOX4 expression positively regulates EGFR levels, we tested whether NOX4 expression decreases Bim exppression. Bim protein levels decreased when NOX4 was overexpressed, whereas they increased when NOX4 was knockdowned ([Figure 5F and 5G](#fig5){ref-type="fig"}). Furthermore, knockdown of another NOX family member, *NOX2*, did not decrease EGFR protein levels or its phosphorylation, whereas *NOX4* knockdown decreased both ([Figure 5H](#fig5){ref-type="fig"}). Consistent with these data, *NOX4* knockdown induced anoikis sensitisation, whereas *NOX2* knockdown had little effect on anoikis ([Figure 5I](#fig5){ref-type="fig"}). Taken together, these data indicate that NOX4 selectively upregulates EGFR protein levels and thus maintains EGFR activity, which likely contributes to anoikis resistance.

EGFR downregulation upon cell detachment
----------------------------------------

Interestingly, our microarray data revealed that *EGFR* expression decreased in suspension-cultured cells ([Figure 6A](#fig6){ref-type="fig"}). Consistent with these data, the mRNA and protein levels of EGFR decreased in a time-dependent manner upon cell detachment ([Figure 6B and C](#fig6){ref-type="fig"}). However, the phosphorylation of EGFR at Tyr 992 and Tyr 1068 remained elevated compared with those of attached cells ([Figure 6C](#fig6){ref-type="fig"}). To determine the role of EGFR in anoikis resistance, we depleted *EGFR* using siRNA in A549 cells. In attached cells, *EGFR* knockdown inhibited cell growth but did not induce cell death. However, in suspended cells, *EGFR* knockdown not only reduced cell aggregate formation but also induced cell death ([Figure 6D](#fig6){ref-type="fig"}). In addition, *EGFR* knockdown resulted in Src inactivation in the suspended cells ([Figure 6E](#fig6){ref-type="fig"}). Furthermore, *EGFR* or *NOX4* knockdown inhibited the colony forming ability of A549 cells under anchorage-independent growth conditions ([Figure 6F](#fig6){ref-type="fig"}). Interestingly, EGFR and NOX4 were upregulated in several lung cancer cell lines, including A549, H1703, Calu-6, H460, H358, and HCC2279 cells, compared with BEAS-2B normal bronchial epithelial cells ([Figure 6G](#fig6){ref-type="fig"}). These data indicate that maintenance of certain levels of EGFR is critical for cell survival when cells are ECM-detached.

NOX4 upregulation is positively correlated with lung cancer
-----------------------------------------------------------

To explore clinical significance of NOX4 expression in the lung cancer patients, we examined NOX4 expression in a lung cancer tissue microarray from 96 patients using anti-NOX4 antibodies or anti-EGFR antibodies. As shown in [Figure 6H](#fig6){ref-type="fig"}, there was little NOX4 expression in the adjacent normal tissues, whereas NOX4 expression was upregulated in the lung cancer tissues. Immunohistochemical analyses showed that NOX4 expression was overall enhanced from the early stage of cancer in about 83% (80/96) of the lung cancer patient tissues ([Table 1](#tbl1){ref-type="table"}). Out of 96 samples, 9 primary tumour samples were obtained from metastatic patients and all of 9 samples showed very strong staining for NOX4. Interestingly, NOX4 expression appeared to be correlated with EGFR expression. For example, NOX4 expression was increased in 96% (43/45) of EGFR-positive lung cancer patients ([Table 2](#tbl2){ref-type="table"}). All these data indicate that NOX4 expression is upregulated in the lung cancer patients and its expression is positively correlated with EGFR expression levels.

Discussion
==========

Upon cell detachment, integrin-mediated cell survival signals are downregulated and apoptosis signals are activated, leading to cell death. This process, known as anoikis, is essential during normal development to get rid of unwanted or mislocalised cells ([@bib11]; [@bib25]). However, cancer cells acquire anoikis resistance to allow for their circulation in the blood or lymphatic system, which is essential for successful cancer metastasis ([@bib20]). Therefore, understanding mechanisms of anoikis resistance could lead to the discovery of therapeutic targets to control or prevent cancer metastasis. In this regard, our present study demonstrated that NOX4 upregulation upon cancer cell detachment was critical for anoikis resistance. We illustrated that NOX4 upregulation resulted in the activation of Src and EGFR, which enhanced cell survival in suspension culture. We also showed that NOX4 overexpression attenuated EGFR downregulation, thereby maintaining levels of EGFR upon cell detachment, and that *NOX4* expression was positively correlated with EGFR levels in lung cancer patients. To our knowledge, these data provide the first evidence that NOX4 expression regulates anoikis resistance via activation of Src and EGFR and upregulation of EGFR levels.

NADPH oxidases of the NOX family are ROS-generating enzymes that regulate redox-dependent signalling pathways associated with cancer development and progression ([@bib3]). NOXs transfer electrons across the cell membrane from NADPH to oxygen, generating superoxide anions, which are then dismutated to form H~2~O~2~. Among NOX family members, NOX4 is unique in that it requires relatively few accessory proteins and preferentially produces H~2~O~2~ rather than superoxide anions ([@bib3]). H~2~O~2~ is known to activates NOX4-derived ROS signalling participates in tumour progression via inhibiting apoptosis, inducing EMT, and promoting cell invasion ([@bib33]; [@bib28]; [@bib5]; [@bib18]; [@bib17]; [@bib1]; [@bib16]; [@bib23]). Because NOX4 is constitutively active, it is thought to be regulated primarily at the gene expression level ([@bib3]). In addition, it has been reported that p22^phox^ upregulation by IGF-1 increases NOX4 activity ([@bib10]). In our study, we found that culturing A549 cells in suspension led to elevated expression of *NOX4* and its partner *p22*^*phox*^ in a time-dependent manner ([Figure 2](#fig2){ref-type="fig"}). Accordingly, upon cell detachment, H~2~O~2~ levels increased and Src activity was elevated. Conversely, treatment with NOX inhibitors, including DPI and apocynin, and siRNA-mediated *NOX4* knockdown decreased Src activation and sensitised cells to anoikis. Treatment with plumbagin, a NOX4 inhibitor ([@bib9]), also sensitised cells to anoikis and decreased ROS levels ([Figure 3](#fig3){ref-type="fig"}). These data indicate that NOX4 upregulation and Src activation are critical for anoikis resistance. To test whether NOX4 upregulation in suspension culture is restricted to the A549 cell line, we employed several lung cancer cell lines, including H1975, H1703 and Calu-6. We found that all three cell lines exhibited cell aggregate formation with little anoikis and NOX4 upregulation in suspension culture ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}), indicating that NOX4 upregulation is not limited to A549 cells. In PC3 cells, ROS production by 5-lipoxygenase (5-LOX) induces Src activation upon cell detachment, which is important for anoikis resistance ([@bib14]). In our study, treatment with the NOX inhibitor DPI sensitised cells to anoikis; however, treatment with the 5-LOX inhibitor nordihydroguaiaretic acid showed little effect on anoikis sensitivity (data not shown), indicating that NOX4 plays the major role in promoting anoikis resistance in A549 cells.

Intriguingly, we found that NOX4 expression was associated not only with EGFR phosphorylation levels but also with its protein expression levels ([Figure 5](#fig5){ref-type="fig"}). It is likely that NOX4 upregulation augments EGFR phosphorylation via H~2~O~2~ because NOX4 preferentially produces H~2~O~2~ rather than superoxide anions ([@bib3]). NOX4 inhibitor, DPI, decreased both ROS generation and EGFR activation ([Figure 3A--C](#fig3){ref-type="fig"}). Another NOX4 inhibitor, plumbagin, also decreased ROS levels and EGFR phosphorylation ([Figure 3E and G](#fig3){ref-type="fig"}). H~2~O~2~ is an important mediator for EGFR phosphorylation induced by various stimuli, including ultraviolet radiation ([@bib26]). We observed that exogenous H~2~O~2~ treatment of A549 cells resulted in EGFR phosphorylation ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). Next, we tested whether NOX2 and NOX4 have a different capacity to generate ROS, and thus affect cell aggregates formation differently. NOX4 knockdown decreased cell aggregate formation within 4 hr in suspended cells whereas NOX2 knockdown affected little ([Supplementary Figure 6A](#sup1){ref-type="supplementary-material"}). Both si-NOX2 and si-NOX4 could reduce ROS levels compared with si-cont but the degree of ROS inhibition was higher in the si-NOX4 cells than in the si-NOX2 ([Supplementary Figure 6B and 6C](#sup1){ref-type="supplementary-material"}). These results correlate with the data in [Figure 5](#fig5){ref-type="fig"} showing that si-NOX4, but not si-NOX2, inhibits EGFR phosphorylation. Therefore, it is possible that H~2~O~2~ induced by NOX4 is responsible for EGFR activation in the suspended cells. Maintenance of EGFR expression levels is important for anoikis resistance ([@bib27]; [@bib14]; [@bib22]). ECM detachment induces a dramatic decrease in EGFR levels, which is responsible for anoikis, and overexpression of EGFR blocks anoikis in MCF-10A human mammary epithelial cells ([@bib27]). In addition, overexpression of ErbB2 increases Sprouty2 protein levels, which inhibits Cbl-induced degradation of EGFR, thereby maintaining EGFR levels ([@bib15]). In our study, *NOX4* knockdown induced anoikis and decreased EGFR levels, whereas NOX4 overexpression attenuated anoikis and EGFR downregulation, suggesting that NOX4 expression is positively linked to EGFR levels. Our data further suggest that NOX4 regulates EGFR at the transcriptional level rather than via the protein degradation pathway, as *NOX4* knockdown decreased *EGFR* at the mRNA level in both attached and suspended cells ([supplementary Figure 3](#sup1){ref-type="supplementary-material"}). In addition, there was little change in levels of Sprouty2, which inhibits the EGFR degradation pathway ([supplementary Figure 3](#sup1){ref-type="supplementary-material"}). A previous study showed that EGFR inhibits anoikis via downregulation of the pro-apoptotic protein Bim ([@bib27]). We also found that, in ECM-detached conditions, Bim protein levels decreased when NOX4 was overexpressed, whereas Bim protein levels increased when *NOX4* was knocked down ([Figure 5F](#fig5){ref-type="fig"}). Therefore, it is likely that NOX4 upregulation maintains EGFR levels upon ECM detachment, leading to Bim downregulation and anoikis resistance.

Several studies indicate that NOX4 is associated with EGFR function. For example, TGF-*β* upregulates NOX4, and this upregulation is important for survival signalling via EGFR transactivation in fetal rat hepatocytes ([@bib24]). Moreover, angiotensin II induces EGFR transactivation via NOX4 during cardiac hypertrophy ([@bib36]) and renal tubular cell dedifferentiation ([@bib8]). In addition, the EGFR tyrosine kinase inhibitor erlotinib induces NOX4 upregulation, which mediates cell survival through activation of cytoprotective autophagy or induction of proinflammatory cytokines, including IL-6, in head and neck cancer cells ([@bib29]). These studies suggest that NOX4 upregulation is associated with cell survival through EGFR modulation. In support of this notion, we demonstrated that NOX4 was upregulated by the unfavorable condition of ECM detachment and that NOX4 was necessary for maintaining EGFR levels and activating EGFR, both of which are critical for anoikis resistance.

Finally, we also showed that knockdown of *EGFR* or *NOX4* in adherent cell culture delayed cell growth but did not induce cell death. However, knockdown of *EGFR* or *NOX4* in suspension cell culture dramatically decreased cell cluster formation and cell survival ([Figures 4](#fig4){ref-type="fig"} and [6](#fig6){ref-type="fig"}), indicating that both molecules are critical for anoikis resistance and tumour progression. Furthermore, our immunocytochemistry analysis using a lung cancer tissue microarray revealed that NOX4 expression was increased in the majority of lung cancer patient samples compared with the adjacent normal tissue samples ([Figure 6H](#fig6){ref-type="fig"}). Bing Liu\'s group also recently reported that NOX4 expression is increased in non-small cell lung cancer patients and this result closely correlates with clinical stage and survival time ([@bib37]). Intriguingly, we found that NOX4 expression is positively correlated with EGFR expression in lung cancer patients ([Table 2](#tbl2){ref-type="table"}). It is possible that high levels of NOX4 not only increase ROS levels to enhance cell survival but also increase or maintain high levels of EGFR to enhance tumour progression as illustrated in the model ([Supplementary Figure 7](#sup1){ref-type="supplementary-material"}). Because it is well known that higher activity of EGFR, via its overexpression or mutation, is associated with cancer progression, it is conceivable that targeting NOX4, and thus disrupting EGFR signalling, is a viable strategy to control cancer progression.
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![**Cell aggregate formation and anoikis resistance in BEAS-2B normal lung epithelial cells and A459 lung cancer cells.** (**A** and **B**) BEAS-2B and A549 cells were cultured in suspension and cell images were captured with a Zeiss inverted microscope at indicated times (**A**), cell numbers were counted by Tryphan blue exclusion assay on indicated days (**B**), and BEAS-2B and A549 cells in suspended for 24 h were analysed of apoptosis with immunoblot of cleaved caspase 3 (**C** and **D**). Equal aliquots of protein (20 *μ*g) from cells grown in attachment or suspension conditions were processed for immunoblot analysis using the indicated antibodies. β-actin was used as a loading control. The data are presented as averages of triplicate measurements with the error bars representing s.d. Scale bar: 100 *μ*m. The experiments were performed three times with similar results.](bjc2016440f1){#fig1}

![**Upregulation of NOX4 and its functional partner p22^phox^ in A459 cells in suspension culture.** (**A**) A549 cells were grown in attached or suspended conditions for 24 h and total RNA was extracted and processed for microarray analysis as described in the 'Materials and Methods\'. (**B--D**) A549 cells were grown in attached or suspended conditions for indicated times followed by total mRNA extraction and cell lysate preparation. The expression levels of *NOX4*, *p22*^*phox*^, *NOX5*, and *NOX2* were determined by RT-PCR or by immunoblotting using the indicated antibodies. The experiments were performed three times with similar results.](bjc2016440f2){#fig2}

![**Association of ROS generation with anoikis resistance in suspended A549 cells.** (**A**) A549 cells were grown in attached or suspended conditions for 24 h. For inhibitor treatments, A549 cells grown in suspension were treated with either 30 *μ*[M]{.smallcaps} of NAC, a ROS scavenger, or 5 *μ*[M]{.smallcaps} of DPI, a pan-NOX inhibitor. The ROS levels were measured by flow cytometry using a ROS-sensitive dye, CM-H~2~DCFDA. (**B**) A549 cells grown in suspension were treated with the NOX inhibitors DPI or apocynin or 24 h, and cell viability was measured using an MTS assay. (**C**) Total cell lysates from A549 cells treated as in **B** were subjected to immunoblotting analysis using the indicated antibodies. (**D--G**) A549 cells grown in suspension were treated with plumbagin for 24 h prior to capturing images of the cell aggregates with a Zeiss inverted microscope (**D**), measuring ROS levels by flow cytometry (**E**), analyzing the levels of cell death by staining with green-fluorescent Calcein AM and red-fluorescent ethidium homodimer-1 (green=live cells; red=dead cells) (**F**), and performing immunoblotting analysis using indicated antibodies (**G**). The ratio of EGFR or phosphorylated EGFR to actin in the control cells was set at 1. Scale bar: 100 *μ*m. The data are presented as averages of triplicate measurements with the error bars representing standard deviations (\**P*\<0.05). These experiments were performed three independent times with comparable results.](bjc2016440f3){#fig3}

![**Effect of NOX4 levels on viability and growth of A549 cells grown in suspension.** (**A**) Mock or NOX4-overexpressing A549 cells were grown in attached or suspended conditions for 24 h. *NOX4* mRNA levels were determined by RT--PCR using *GAPDH* as a loading control. Nox4 protein levels were determined by immunoblotting using the indicated antibodies. (**B**) Mock or NOX4-overexpressing A549 cells were transfected with non-specific siRNA (si-control) or with siRNA specific for *NOX4* (si-*NOX4*) for 24 h, and the levels of *NOX4* mRNA were determined by RT--PCR. Nox4 protein levels were determined by immunoblotting using the indicated antibodies. (**C**) Mock or NOX4-overexpressing A549 cells were transfected with si-control or si-*NOX4* and were grown in attached or suspended conditions for 24 h. The cells were imaged using a Zeiss inverted microscope. (**D--F**) A549 cells were transfected with si-control or si-*NOX4* and were grown in suspended conditions for 24 h. The cells were subjected to viability analysis (**D**), immunoblotting analysis (**E**), and cell counting at the indicated times (**F**). Scale bar: 100 *μ*m. The data are presented as averages of triplicate measurements with the error bars representing standard deviations (\**P*\<0.05). Similar results were observed in three independent experiments.](bjc2016440f4){#fig4}

![**Association of NOX4 and EGFR levels in A549 cells.** (**A** and **G**) A549 cells were transfected with si-control or with si-*NOX4* and were grown in attached or suspended conditions for 24 h, followed by immunoblotting analysis. The levels of EGFR were quantified by a densitometry and normalised to β-actin levels. The ratio of EGFR to actin in the attached/control cells was set at 1. (**B** and **C**) A549 cells were transfected with si-control or with si-*NOX4* for 24 h. The cells were processed for immunofluorescence analysis (**B**) or flow cytometry analysis (**C**). Non-specific IgG was used as a negative control for EGFR staining. (**D** and **F**) Mock or NOX4-overexpressing A549 cells were grown in attached or suspended conditions for 24 h, followed by immunoblotting analysis. (**E**) Mock or NOX4-overexpressing A549 cells were transfected with si-control or with si-*NOX4*, and then were grown in suspended condition for 24 h, followed by immunoblotting analysis. The levels of EGFR were quantified by a densitometry and normalised to β-actin levels. The ratio of EGFR to actin was set at 1 either in the Mock/control cells (**E**) or in the si-control cells (**H**), respectively. (**H** and **I**) A549 cells were transfected with si-control, si-*NOX4*, or si-*NOX2* and were grown in suspended conditions for 24 h, followed by immunoblotting analysis (**H**) or cell imaging (**I**). Scale bars: 20 *μ*m in **B**. Scale bars: 100 *μ*m in **I**. The data are presented as averages of triplicate measurements with the error bars representing standard deviations (\**P*\<0.05). Similar results were observed in three independent experiments.](bjc2016440f5){#fig5}

![**Association of EGFR levels with anoikis sensitivity in A549 cells.** (**A**) A549 cells were grown in attached or suspended conditions for 24 h, and total RNA was extracted and processed for expression microarray. (**B** and **C**) A549 cells were grown in attached or suspended conditions for 24 h or indicated times, followed by total mRNA extraction for RT-PCR (**B**) and cell lysate preparation for immunoblotting analysis (**C**). (**D** and **E**) A549 cells were transfected with si-control or si-*EGFR* RNAs and were grown in attached or suspended conditions for 24 h, followed by cell viability analysis (**D**) or immunoblotting analysis (**E**). (**F**) A549 cells were transfected with si-control, si-*EGFR*, or si-*NOX4*, and 1 × 10^3^ cells/well of a 35 mm culture plate were seeded and cultured in soft agar medium for 2 weeks, followed by staining with INT and imaging. (**G**) Cell lysates from BEAS-2B, A549, H1703, Calu-6, H460, H358 and HCC2270 cell lines were analysed by immunoblotting using anti-EGFR and anti-NOX4 antibodies. Similar results were observed in three independent experiments. (**H**) A patient-derived lung cancer tissue microarray was examined for NOX4 and EGFR expression using an immunoperoxidase method and isotype IgG was used as a control for staining. The staining results were graded according to intensity and proportion of positive cells described in the 'Materials and Methods\' section.](bjc2016440f6){#fig6}

###### Summary of NOX4 expression and clinicopathological feature in the lung cancer patients

                              **NOX4 expression**               
  ---------------------- ---- --------------------- ----------- -------
  **Sex**                                                       
  Male                   76   11 (14.5)             65 (85.5)   0.372
  Female                 20   5 (25)                15 (75)      
  **Age**                                                       
  ⩽57                    34   9 (26.5)              26 (73.5)   0.48
  \>57                   62   7 (11.3)              55 (88.7)    
  **Clinical stage**                                            
  I                      36   6 (16.7)              30 (83.3)   0.51
  II                     38   6 (15.8)              32 (84.2)    
  II                     22   4 (18.2)              18 (81.8)    
  **N classification**                                          
  N~0~                   55   9 (16.4)              46 (83.6)   0.20
  N~1~                   24   4 (16.7)              20 (83.3)    
  N~2~                   17   3 (13.6)              14 (63.6)    
  **T classification**                                          
  T~1~                   8    2 (25)                6 (75)      0.52
  T~2~                   72   11 (15.3)             61 (84.7)    
  T~3~                   10   3 (30)                7 (70)       
  T~4~                   6    0 (0)                 6 (100)      
  **Histology**                                                 
  Adenocarcinoma         26   6 (23)                20 (77)      
  Squamous carcinoma     49   6 (12)                43 (88)     0.682
  Others                 21   4 (19)                17 (81)     0.5

###### Summary of NOX4 and EGFR expression in the lung cancer tissues

                  **NOX4 expression (*****P*****\<0.01)**                
  --------------- ----------------------------------------- ------------ ----------
  EGFR (−,+)      14 (27.5%)                                37 (72.5%)   51 (53%)
  EGFR (++,+++)   2 (4%)                                    43 (96%)     45 (47%)
  Total           16 (17%)                                  80 (83%)     96 (100)

Abbreviation: EGFR=epidermal growth factor receptor.
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